连续葡萄糖监测与间歇扫描式连续葡萄糖监测在2型糖尿病患者中的疗效与安全性:介入性证据的系统综述与Meta分析
该系统综述与Meta分析纳入26项随机对照试验共2783例2型糖尿病患者,评估连续葡萄糖监测(CGM)和间歇扫描式CGM(isCGM)对比常规护理或自我血糖监测(SMBG)的获益与风险。CGM降低HbA1c(平均差-0.19% [95% CI -0.34, -0.04])和降糖药物效应评分(-0.67 [-1.20, -0.13]),降低用户满意度(-0.54 [-0.98, -0.11]),增加不良事件风险(RR 1.22 [95% CI 1.01, 1.47]);isCGM降低HbA1c(-0.31% [-0.46, -0.17]),提高用户满意度(0.44 [0.29, 0.59]),改善CGM指标,增加不良事件风险(RR 1.30 [0.05, 1.62])。两者对体成分、血压或血脂均无显著影响。
要点
- CGM降低2型糖尿病患者HbA1c(平均差-0.19%)但降低用户满意度并增加不良事件风险(RR 1.22)。
- isCGM降低HbA1c(-0.31%)并提高用户满意度(0.44),同时增加不良事件风险(RR 1.30)。
- CGM与isCGM对体成分、血压或血脂均无显著影响。
核心结论
- CGM和isCGM均降低2型糖尿病患者的HbA1c水平;与CGM不同,isCGM使用与用户满意度改善相关。
- 这些设备对体成分、血压和血脂的影响仍不明确,而CGM和isCGM使用均与不良事件风险增加相关。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、Cochrane Library、Web of Science及参考文献至2023年8月。
- 纳入26项随机对照试验(17项CGM和9项isCGM),共2783例2型糖尿病患者(CGM 632例 vs 常规护理/SMBG 514例;isCGM 871例 vs 常规护理/SMBG 766例)。
- 纳入标准为在2型糖尿病患者中比较至少两种干预≥8周的随机对照试验,干预包括实时/回顾性CGM、短期/长期CGM、isCGM和SMBG,报告血糖及相关数据。
主要发现
- CGM降低HbA1c(平均差-0.19% [95% CI -0.34, -0.04])和降糖药物效应评分(-0.67 [-1.20, -0.13]),降低用户满意度(-0.54 [-0.98, -0.11]),增加不良事件风险(RR 1.22 [95% CI 1.01, 1.47])。
- isCGM降低HbA1c(-0.31% [-0.46, -0.17]),提高用户满意度(0.44 [0.29, 0.59]),改善CGM指标,增加不良事件风险(RR 1.30 [0.05, 1.62])。
- CGM和isCGM对体成分、血压或血脂水平均无显著影响。
局限性
- 局限性包括样本量小、单研究结局、人群差异以及对年轻成人的不确定性。
- 此外,大多数终点纳入的研究<10项限制了全面分析,且需考虑随时间推移的技术进步。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traditional diabetes self-monitoring of blood glucose (SMBG) involves inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems offer CGM, enhancing type 2 diabetes (T2D) management with convenient, comprehensive data. PURPOSE: To assess the benefits and potential harms of CGM and isCGM compared with usual care or SMBG in individuals with T2D. DATA SOURCES: We conducted a comprehensive search of MEDLINE, Embase, the Cochrane Library, Web of Science, and bibliographies up to August 2023. STUDY SELECTION: We analyzed studies meeting these criteria: randomized controlled trials (RCT) with comparison of at least two interventions for ≥8 weeks in T2D patients, including CGM in real-time/retrospective mode, short-/long-term CGM, isCGM, and SMBG, reporting glycemic and relevant data. DATA EXTRACTION: We used a standardized data collection form, extracting details including author, year, study design, baseline characteristics, intervention, and outcomes. DATA SYNTHESIS: We included 26 RCTs (17 CGM and 9 isCGM) involving 2,783 patients with T2D (CGM 632 vs. usual care/SMBG 514 and isCGM 871 vs. usual care/SMBG 766). CGM reduced HbA1c (mean difference -0.19% [95% CI -0.34, -0.04]) and glycemic medication effect score (-0.67 [-1.20 to -0.13]), reduced user satisfaction (-0.54 [-0.98, -0.11]), and increased the risk of adverse events (relative risk [RR] 1.22 [95% CI 1.01, 1.47]). isCGM reduced HbA1c by -0.31% (-0.46, -0.17), increased user satisfaction (0.44 [0.29, 0.59]), improved CGM metrics, and increased the risk of adverse events (RR 1.30 [0.05, 1.62]). Neither CGM nor isCGM had a significant impact on body composition, blood pressure, or lipid levels. LIMITATIONS: Limitations include small samples, single-study outcomes, population variations, and uncertainty for younger adults. Additionally, inclusion of <10 studies for most end points restricted comprehensive analysis, and technological advancements over time need to be considered. CONCLUSIONS: Both CGM and isCGM demonstrated a reduction in HbA1c levels in individuals with T2D, and unlike CGM, isCGM use was associated with improved user satisfaction. The impact of these devices on body composition, blood pressure, and lipid levels remains unclear, while both CGM and isCGM use were associated with increased risk of adverse events.
引用
- Seidu S, Kunutsor SK, Ajjan RA, et al. Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence. Diabetes Care. 2024. PMID: 38117991. doi:10.2337/dc23-1520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。